Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology

Phase 3 data (Abstract LBA7008) featured in the official press program of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine

Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical OncologyHORSHAM, PA, June 2, 2014 – Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use of abiraterone acetate plus prednisone (5 mg once daily) in patients with non-metastatic castration-resistant prostate cancer (M0-CRPC) at high risk of developing metastatic disease.

Getting Back to Giving Back campaign celebrates and shares the inspirational stories of those who have had joint replacement and returned to helping causes that bring hope and relief to those in need

WARSAW, IN – (May 22, 2014) DePuy Synthes Joint Reconstruction*, a global leader in joint replacement solutions, announced today the introduction of three new products for hip, knee and shoulder replacement. These products are key examples of how the company is advancing patient care while also making surgical processes and procedures more efficient for surgeons and the health care system overall.

Not taking medication correctly, or forgetting altogether, can have a significant impact on health, often resulting in delayed recovery or even hospitalisation6. 

More than 30 major product filings planned through 2016Leading the industry in emerging market salesNew Brunswick, N.J.

LEIDEN, THE NETHERLANDS, May 19, 2014 – Janssen Biologics B.V.

Breakthrough technology redefines ultrasonic energy with HARMONIC® promise of precision, now combined with larger vessel sealingFirst purely ultrasonic device with a 7mm vessel sealing indication

Simeprevir provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe

San Diego, CA, May 14, 2014 — Janssen Labs, part of Janssen Research & Development, LLC (Janssen), today announced plans to open Janssen Labs @South San Francisco, a new 30,000-square foot, standalone operation based at 329 Oyster Point Boulevard, South San Francisco, CA. The new location will accommodate up to 50 independent, emerging companies to be co-located with staff from Johnson & Johnson Innovation, LLC.

New submission based on positive data from a 15-month schizoaffective relapse prevention study

Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide

Filing Includes Data from Treatment-Naïve Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning

First prospective, randomized clinical trial to reflect context of “real world” issues in treating schizophrenia, including recent incarceration and substance abuse

Future Care Scholarships Help Support Students Pursuing Careers in Healthcare IndustryFt. Washington, PA, May 1, 2014 – McNeil Consumer Healthcare Division of McNEIL-PPC, Inc., the makers of TYLENOL®, announces the 24th annual TYLENOL® Future Care Scholarship, and is now accepting applications through June 30, 2014.

New Brunswick, NJ – April 29, 2014 – Johnson & Johnson today announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF), to facilitate access to the Company’s anti-tuberculosis medicine. This public-private partnership was established by the newly formed Janssen Global Public Health and is the latest in the Company’s overall efforts to improve public health.

Proven Principles in Sport Science and Energy Management Shed New Light on Improving Health OutcomesNew York, NY (April 29, 2014) –Johnson & Johnson announced today, in partnership with the American College of Sports Medicine (ACSM), the creation of the Global Alliance for Health and Performance (the Global Alliance). The Global Alliance will work to educate and promote the ways in which proven principles of sport science and energy management can move society from a disease state to a performance state.

BEERSE, April 25 2014 – Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.[1] Canagliflozin as a single agent was approved as INVOKANA® in the European Union in November 2013.[2]

New Brunswick, NJ (April 24, 2014) – Johnson & Johnson today announced that its Board of Directors has declared a 6.1% increase in the quarterly dividend rate, from $0.66 per share to $0.70 per share.  The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, NJ.“In recognition of our 2013 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the dividend for the 52nd consecutive year,” said Alex Gorsky, Chairman and Chief Executive Officer of the Company.

First treatment approved for patients with rare blood disorder

New Brunswick, NJ (April 23, 2014) – Johnson & Johnson (NYSE: JNJ) will host a review of its Medical Devices & Diagnostics business for the investment community beginning at 9:30 a.m. (Eastern Time) on Thursday, May 22, 2014 at the Hyatt Regency Hotel in New Brunswick, New Jersey and ending at approximately 2:30 p.m.Dominic J. Caruso, Vice President, Finance and Chief Financial Officer will host the meeting which will feature presentations by Johnson & Johnson’s senior management within the Medical Devices and Diagnostics organization.

FORT WASHINGTON, PA (April 16, 2014) – To help food enthusiasts in their pursuit of elevated tastes, the makers of PEPCID® are teaming with culinary expert Ted Allen and Eater.com to launch the PEPCID® Tastemakers Series. Heartburn doesn’t just affect those chowing down on massive plates of hot wings or indulging in fried food at the ballpark. Heartburn can strike anywhere, even after a decadent meal at a Michelin-starred restaurant.

Sales of $18.1 Billion increased 3.5% Versus 2013 First Quarter;First-Quarter EPS was $1.64Excluding Special Items, 2014 First-Quarter EPS of $1.54 increased 6.9%*

Additional Studies Presented in Genotype 1 and Genotype 4 Hepatitis C Patient Subgroups Underscore Benefit of Simeprevir-based Treatment Regimens

New submission based on positive Phase 3 data from the RESONATE™ trial

OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin

RARITAN, NJ, April 1, 2014– Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir, a protease inhibitor developed by Janssen R&D Ireland and marketed as PREZISTA® in the U.S., with cobicistat, an investigational pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc.

Bethesda, MD (April 1, 2014) – Johnson & Johnson announced it has entered a multi-year agreement to be the Official Healthcare Partner of the USO.  The announcement was made today during a ceremony to mark the opening of the USO’s Warrior and Family Center at Bethesda, located on the campus of Naval Support Activity Bethesda, home of Walter Reed National Military Medical Center.

Raritan, NJ (March 31, 2014) — Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO® (rivaroxaban), the most studied and broadly indicated oral Factor Xa inhibitor in the world today. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient populations, including those at risk for DVT or PE due to a concurrent medical illness.

New Brunswick, NJ, March 31, 2014 -- Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. This acceptance was made after consultation with the relevant works councils and trade unions. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions.

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab

Beerse / Belgium, March 21, 2014 – Janssen-Cilag International NV (“Janssen”) announced today that The Committee for Medical Products for Human Use (CHMP) of The European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a marketing authorisation for siltuximab for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative.1 If approved, siltuximab would be the first medicine to receive regulatory approval in the EU for treatment of MCD patients.

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment EfficacyTitusville, NJ – (March 20, 2014) - Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of paliperidone palmitate 3-month formulation, an investigational treatment for symptoms of schizophrenia in adults. 

Solutions include MedTrak, Inc.’s CareSense System To Track and Analyze Patient Outcomes, Patient Satisfaction and Cost     RAYNHAM, MA – (March 13, 2014) – Today DePuy Synthes Companies of Johnson & Johnson introduced DePuy Synthes Advantage™, a unique suite of provider-focused solutions focused on complementing the company’s extensive portfolio of clinically proven products with solutions that assist in driving optimal clinical and economic outcomes while striving to improve the patient experience.

WARSAW, IN – (March 12, 2014) – DePuy Synthes Joint Reconstruction*, a global leader in joint replacement, today announced the introduction of two new technologies for the ATTUNE® Knee System—the ATTUNE Rotating Platform Knee and the Anatomic Patella. The announcement was made in conjunction with the 2014 American Academy of Orthopaedic Surgeons Meeting (AAOS) in New Orleans.

New Brunswick, NJ (March 11, 2014) - Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15th, to review first-quarter results.   Dominic Caruso, Vice President, Finance and Chief Financial Officer and Louise Mehrotra, Vice President, Investor Relations, will host the call.Investors and other interested parties may access the conference call in the following ways:

New form provides a convenient solution for powerful allergy reliefFORT WASHINGTON, PA (March 5, 2014) – The makers of ZYRTEC® are pleased to announce the launch of a new form to the ZYRTEC® portfolio of allergy-relief products – a convenient oral, dissolvable tablet.  Delivering the same effective 24-hour relief, ZYRTEC® Dissolve Tabs are now available for adults and children, age 6 years and above, and can be purchased at all major retailers and pharmacies.